Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 113 articles: HTML format

Single Articles

August 2026
1. VAJA S, Dickson JL, Horst C, Mullin ML, et al
   The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility.
   Br J Cancer. 2026 Aug 7. doi: 10.1038/s41416-026-03578.
   PubMed     Abstract available
   
   
   July 2026
2. SUN M, Zang D, Chen J
   Clarifying causal and translational inference in studies of ambient PM2.5 and lung cancer.
   Br J Cancer. 2026 Jul 27. doi: 10.1038/s41416-026-03555.
   PubMed    
   
   
   
3. ALHATTAB RAN, McKinley JM, Hunter RF, Delargy CM, et al
   Reply to 'Clarifying causal and translational inference in studies of ambient PM(2.5) and lung cancer'.
   Br J Cancer. 2026 Jul 20. doi: 10.1038/s41416-026-03554.
   PubMed    
   
   
   
4. LI Q, Yuan H, Li L, Zhao G, et al
   Altretamine induces ferroptosis in small cell lung cancer by promoting epigenetic silencing and lysosomal degradation of GPX4.
   Br J Cancer. 2026 Jul 2. doi: 10.1038/s41416-026-03531.
   PubMed     Abstract available
   
   
   June 2026
5. NAVARATNAM S
   Can national lung cancer screening programs be implemented without exacerbating social disparities?
   Br J Cancer. 2026 Jun 30. doi: 10.1038/s41416-026-03525.
   PubMed     Abstract available
   
   
   
6. CHEN F, Chen Y, Sun W, Ma H, et al
   Anti-PDGFRalpha autoantibody - a novel diagnostic and prognostic marker - may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-kappaB signaling pathway.
   Br J Cancer. 2026 Jun 27. doi: 10.1038/s41416-026-03501.
   PubMed     Abstract available
   
   
   
7. LIU C, Fukuda E, Sagiya Y, Tsuru H, et al
   Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma.
   Br J Cancer. 2026 Jun 25. doi: 10.1038/s41416-026-03504.
   PubMed     Abstract available
   
   
   
8. HIGASHIYAMA RI, Yoshida T, Shiraishi K, Miyakoshi J, et al
   Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer.
   Br J Cancer. 2026 Jun 2. doi: 10.1038/s41416-026-03457.
   PubMed     Abstract available
   
   
   
9. CHEN Y, Chen Q, Li Q, Guo J, et al
   A novel microprotein L3EMP triggers lung adenocarcinoma progression by catalysing the deubiquitination of SIRT1.
   Br J Cancer. 2026;134:1541-1556.
   PubMed     Abstract available
   
   
   
10. WANG X, Xie Y, Hu J, Liu N, et al
    Furmonertinib combined with bevacizumab in EGFR-TKI-resistant leptomeningeal metastasis: analysis of the CSF ctDNA molecular response and survival outcomes.
    Br J Cancer. 2026;134:1614-1623.
    PubMed     Abstract available
    
    
    
11. LOPEZ JS, Harrington KJ, Im SA, Lee KW, et al
    Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
    Br J Cancer. 2026;134:1568-1579.
    PubMed     Abstract available
    
    
    
12. MICHAEL A, Huynh J, Sutton K, Chow MC, et al
    The utility of electronic frailty index in cancer patients undergoing chemotherapy.
    Br J Cancer. 2026;134:1793-1800.
    PubMed     Abstract available
    
    
    
13. SUN S, Ma G, Cheng L, Zhang H, et al
    Novel transcription factor zinc finger 514 suppresses lung adenocarcinoma progression and enhances cisplatin sensitivity via transcriptional repression of COL1A1.
    Br J Cancer. 2026;134:1716-1729.
    PubMed     Abstract available
    
    
    May 2026
14. PARK SS, Lee HW, Kwon MR, Ju EJ, et al
    Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells.
    Br J Cancer. 2026 May 26. doi: 10.1038/s41416-026-03475.
    PubMed     Abstract available
    
    
    
15. SKRIBEK M, Livanou ME, Vathiotis I, Strandman V, et al
    The brain-lung immunotherapy prognostic (BLIP) Score: a novel robust tool for prognostication in non-small cell lung cancer patients with brain metastases.
    Br J Cancer. 2026 May 20. doi: 10.1038/s41416-026-03470.
    PubMed     Abstract available
    
    
    April 2026
16. CHOI E, Luo S, Ding VY, Graber-Nadich A, et al
    Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.
    Br J Cancer. 2026 Apr 27. doi: 10.1038/s41416-026-03454.
    PubMed     Abstract available
    
    
    
17. ZHAO K, Zhang J, Wang R, Wang B, et al
    STAT3 signaling mediates EGFR-TKI resistance in non-small cell lung cancer by regulating stemness markers and telomerase, reversed by icaritin.
    Br J Cancer. 2026 Apr 22. doi: 10.1038/s41416-026-03433.
    PubMed     Abstract available
    
    
    
18. OZAWA Y, Yamamoto K, Sugawara S, Niho S, et al
    Impact of tumor location on the efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer.
    Br J Cancer. 2026 Apr 9. doi: 10.1038/s41416-026-03406.
    PubMed     Abstract available
    
    
    
19. ZHANG J, Liu Y, Yuan H, Zhan N, et al
    Molecular phenotypes stratify small cell lung cancer for targeted therapy and immunotherapy.
    Br J Cancer. 2026 Apr 3. doi: 10.1038/s41416-026-03390.
    PubMed     Abstract available
    
    
    
20. JOHNSON ML, Fabbri G, Ciardullo C, Wang JS, et al
    Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.
    Br J Cancer. 2026 Apr 3. doi: 10.1038/s41416-026-03414.
    PubMed     Abstract available
    
    
    
21. HUANG Q, Zhao J, Zhang Y, Zhou Y, et al
    eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia.
    Br J Cancer. 2026;134:996-1005.
    PubMed     Abstract available
    
    
    March 2026
22. RAMESH V, Demirdizen M, Pinna L, Doktor TK, et al
    Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role.
    Br J Cancer. 2026;134:799-810.
    PubMed     Abstract available
    
    
    
23. DONG Z, Xie W, Zhang N, Guo Y, et al
    Myc-mediated epigenetic silencing of ACAP3 promotes lung adenocarcinoma proliferation via regulating EGFR dynamics.
    Br J Cancer. 2026;134:860-873.
    PubMed     Abstract available
    
    
    February 2026
24. TSUCHIDA S, Taki T, Nomura K, Suzuki K, et al
    Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness.
    Br J Cancer. 2026;134:567-576.
    PubMed     Abstract available
    
    
    January 2026
25. GALAL B, Dennis J, Antoniou AC, Harrison H, et al
    The current state of polygenic scores for the development of lung cancer: a systematic review and validation in UK Biobank.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03330.
    PubMed     Abstract available
    
    
    
26. DE RUITER JC, van der Noort V, van Diessen JNA, Smit EF, et al
    Stage I non-small cell lung cancer: improving patient selection for minimally invasive lobectomy or stereotactic ablative radiotherapy based on clinical characteristics.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03332.
    PubMed     Abstract available
    
    
    
27. WANG M, Fan J, Mu B, Zeng Y, et al
    HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03328.
    PubMed     Abstract available
    
    
    
28. ROSEN JC, Cao P, Pham NA, Waas M, et al
    Modeling response to the KRAS-G12C inhibitor AZD4625 in KRAS(G12C) NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms.
    Br J Cancer. 2026;134:165-174.
    PubMed     Abstract available
    
    
    December 2025
29. ERNHOFER B, Solta A, Sinner J, Megyesfalvi Z, et al
    Fibroblast growth factor signals drive the metastatic behavior in small cell lung cancer.
    Br J Cancer. 2025 Dec 13. doi: 10.1038/s41416-025-03276.
    PubMed     Abstract available
    
    
    
30. GUO Z, Chen J, Zhang S, Xie J, et al
    RNLS hypomethylation as a potential epigenetic marker of lung cancer metastasis: an epigenome-wide association study.
    Br J Cancer. 2025 Dec 10. doi: 10.1038/s41416-025-03283.
    PubMed     Abstract available
    
    
    
31. HUANG P, He S, Qi Z, Nijiati Y, et al
    ENO1 promotes cancer metastasis via stimulating metabolism reprogramming in osteosarcoma.
    Br J Cancer. 2025;133:1625-1639.
    PubMed     Abstract available
    
    
    November 2025
32. DAI S, Liu Y, Guo T, Luo H, et al
    Systemic activation and tissue infiltration of CD8 + CX3CR1 + T cells in non-small cell lung cancer treated with neoadjuvant immune checkpoint blockade.
    Br J Cancer. 2025 Nov 22. doi: 10.1038/s41416-025-03160.
    PubMed     Abstract available
    
    
    
33. XIAO Y, Luo Y, Mao D, Zhang L, et al
    Metabolic dysregulation associated with core symptom cluster in lung cancer patients undergoing chemotherapy.
    Br J Cancer. 2025 Nov 13. doi: 10.1038/s41416-025-03262.
    PubMed     Abstract available
    
    
    
34. LI W, Pei W, Wang Y, Nie J, et al
    Unraveling cellular dynamic changes in tumor evolution induced by long-term low dose-rate radiation.
    Br J Cancer. 2025;133:1278-1296.
    PubMed     Abstract available
    
    
    
35. SCHELCH K, Maach N, Hashim M, Zitta B, et al
    Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma.
    Br J Cancer. 2025;133:1391-1400.
    PubMed     Abstract available
    
    
    
36. BAIRD L, Zhang L, Hidaka T, Xi L, et al
    Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs.
    Br J Cancer. 2025;133:1377-1390.
    PubMed     Abstract available
    
    
    
37. HAMZA A, Gestraud P, Karimi M, Tran-Dien A, et al
    Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent bi
    Br J Cancer. 2025;133:1554-1564.
    PubMed     Abstract available
    
    
    October 2025
38. ALHATTAB RAN, McKinley JM, Hunter RF, Delargy CM, et al
    Lung cancer burden attributable to ambient particulate matter: a nationally representative population-based case-control study.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03207.
    PubMed     Abstract available
    
    
    
39. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    PubMed     Abstract available
    
    
    
40. SAKAI SA, Oyoshi H, Nakamura M, Taki T, et al
    Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy.
    Br J Cancer. 2025;133:795-808.
    PubMed     Abstract available
    
    
    
41. JING P, Liang Y, Tan Z, Yan X, et al
    Physiological and psychological symptom management based on electronic patient-reported outcomes: the TD-WELLBEING randomized clinical trial.
    Br J Cancer. 2025;133:937-944.
    PubMed     Abstract available
    
    
    
42. RUBIO-SAN-SIMON A, Wilson W, Sironi G, le Deley MC, et al
    Prognostic factors in patients with relapsed high-grade osteosarcoma: a systematic review.
    Br J Cancer. 2025;133:1020-1028.
    PubMed     Abstract available
    
    
    September 2025
43. TAKEZAWA K, Okamoto I, Tsukioka S, Uchida J, et al
    Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03211.
    PubMed    
    
    
    August 2025
44. ROCCA A, Crino L, Braga L, Salton F, et al
    Refining treatment strategies for non-small cell lung cancer lacking actionable mutations: insights from multi-omics studies.
    Br J Cancer. 2025 Aug 23. doi: 10.1038/s41416-025-03139.
    PubMed     Abstract available
    
    
    
45. LI J, Liu Y, Zhang L, Xing Y, et al
    An intelligent diagnostic model for pulmonary nodules utilizing chest radiographic imagery and its application in community-based lung cancer screening.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03147.
    PubMed     Abstract available
    
    
    
46. GONG B, Guo Y, Wan Q, Lou J, et al
    The lung immune prognostic index stratifies the occurrence of checkpoint inhibitor pneumonitis in advanced non-small cell lung cancer patients: a multi-institutional cohort study.
    Br J Cancer. 2025 Aug 15. doi: 10.1038/s41416-025-03124.
    PubMed     Abstract available
    
    
    July 2025
47. SHIMAUCHI A, Iwama E, Ibusuki R, Tsutsumi H, et al
    Enhanced HER2 internalization by clathrin-dependent endocytosis in non-small cell lung cancer positive for HER2 mutations.
    Br J Cancer. 2025 Jul 28. doi: 10.1038/s41416-025-03126.
    PubMed     Abstract available
    
    
    
48. NITSCHKOWSKI D, Vierbuchen T, Heine H, Behrends J, et al
    SMAD2 linker phosphorylation impacts overall survival, proliferation, TGFbeta1-dependent gene expression and pluripotency-related proteins in NSCLC.
    Br J Cancer. 2025;133:52-65.
    PubMed     Abstract available
    
    
    June 2025
49. GURNEY J, Davies A, Stanley J, Dunn A, et al
    National variation in the treatment of lung cancer in a universal healthcare context.
    Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03071.
    PubMed     Abstract available
    
    
    May 2025
50. THOMAS C, Heathcote L, Sun Y, Callister MEJ, et al
    Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England.
    Br J Cancer. 2025 May 14. doi: 10.1038/s41416-025-03043.
    PubMed     Abstract available
    
    
    April 2025
51. HUGHES DJ, Chand G, Johnson J, Tegala R, et al
    PD-L1 imaging with [(99m)Tc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.
    Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02991.
    PubMed     Abstract available
    
    
    
52. COLANGELO T, Mazzarelli F, Cuttano R, Dama E, et al
    Unveiling the origin and functions of diagnostic circulating microRNAs in lung cancer.
    Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02982.
    PubMed     Abstract available
    
    
    
53. WANG M, Kim RY, Kohonen-Corish MRJ, Chen H, et al
    Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence.
    Br J Cancer. 2025 Apr 4. doi: 10.1038/s41416-025-02999.
    PubMed     Abstract available
    
    
    
54. LIN X, Liu Z, Zhou K, Li Y, et al
    Intratumoral and peritumoral PET/CT-based radiomics for non-invasively and dynamically predicting immunotherapy response in NSCLC.
    Br J Cancer. 2025;132:558-568.
    PubMed     Abstract available
    
    
    
55. ZHANG W, Wang J, Liang J, He Z, et al
    RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC.
    Br J Cancer. 2025;132:569-579.
    PubMed     Abstract available
    
    
    
56. HONG CT, Yang YE, Juan HF, Chang CP, et al
    GDP-bound Rab37 modulates M2-like tumor-associated macrophage polarization by attenuating STAT1 translocation to downregulate the type I IFN pathway.
    Br J Cancer. 2025;132:622-634.
    PubMed     Abstract available
    
    
    January 2025
57. WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al
    Correction: Cardiotoxicity following thoracic radiotherapy for lung cancer.
    Br J Cancer. 2025 Jan 7. doi: 10.1038/s41416-024-02926.
    PubMed    
    
    
    December 2024
58. CUTTY SJ, Hughes FA, Ortega-Prieto P, Desai S, et al
    Pro-survival roles for p21(Cip1/Waf1) in non-small cell lung cancer.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02928.
    PubMed     Abstract available
    
    
    
59. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    
60. POPAT S, Januszewski A, O'Brien M, Ahmad T, et al
    Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.
    Br J Cancer. 2024 Dec 5. doi: 10.1038/s41416-024-02901.
    PubMed     Abstract available
    
    
    November 2024
61. NORONHA V, Menon N, Patil VM, Shah M, et al
    Pregabalin for chronic cough due to lung cancer: randomized, double-blind, placebo-controlled trial.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02913.
    PubMed     Abstract available
    
    
    
62. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    PubMed     Abstract available
    
    
    
63. WALLS GM, Bergom C, Mitchell JD, Rentschler SL, et al
    Cardiotoxicity following thoracic radiotherapy for lung cancer.
    Br J Cancer. 2024 Nov 6. doi: 10.1038/s41416-024-02888.
    PubMed     Abstract available
    
    
    
64. HEKTOEN HH, Tsuruda KM, Fjellbirkeland L, Nilssen Y, et al
    Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study.
    Br J Cancer. 2024 Nov 3. doi: 10.1038/s41416-024-02895.
    PubMed     Abstract available
    
    
    
65. WEI J, Zhou S, Chen G, Chen T, et al
    GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression.
    Br J Cancer. 2024;131:1529-1542.
    PubMed     Abstract available
    
    
    
66. CHANDOURI B, Naves T, Yassine M, Ikhlef L, et al
    Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC.
    Br J Cancer. 2024;131:1425-1436.
    PubMed     Abstract available
    
    
    
67. LIU X, Min Q, Cheng X, Zhang W, et al
    Quiescent cancer cells induced by high-density cultivation reveals cholesterol-mediated survival and lung metastatic traits.
    Br J Cancer. 2024;131:1591-1604.
    PubMed     Abstract available
    
    
    October 2024
68. WANG Y, Ju X, Hua R, Chen J, et al
    Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.
    Br J Cancer. 2024 Oct 25. doi: 10.1038/s41416-024-02856.
    PubMed     Abstract available
    
    
    
69. MANDAL T, Shukla D, Khan MMA, Ganesan SK, et al
    The EXO1/Poleta/Poliota axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02840.
    PubMed     Abstract available
    
    
    August 2024
70. MIGLIETTA G, Russo M, Capranico G, Marinello J, et al
    Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?
    Br J Cancer. 2024 Aug 31. doi: 10.1038/s41416-024-02821.
    PubMed     Abstract available
    
    
    
71. ABDIPOURBOZORGBAGHI M, Vancura A, Radpour R, Haefliger S, et al
    Circulating miRNA panels as a novel non-invasive diagnostic, prognostic, and potential predictive biomarkers in non-small cell lung cancer (NSCLC).
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02831.
    PubMed     Abstract available
    
    
    
72. ROGERS I, Cooper M, Memon A, Forbes L, et al
    The effect of comorbidities on diagnostic interval for lung cancer in England: a cohort study using electronic health record data.
    Br J Cancer. 2024 Aug 23. doi: 10.1038/s41416-024-02824.
    PubMed     Abstract available
    
    
    
73. NAGELBERG AL, Sihota TS, Chuang YC, Shi R, et al
    Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response.
    Br J Cancer. 2024;131:534-550.
    PubMed     Abstract available
    
    
    
74. BUDCZIES J, Romanovsky E, Kirchner M, Neumann O, et al
    KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
    Br J Cancer. 2024;131:524-533.
    PubMed     Abstract available
    
    
    July 2024
75. JEONG H, Koh J, Kim S, Song SG, et al
    Correction: Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Br J Cancer. 2024 Jul 30. doi: 10.1038/s41416-024-02798.
    PubMed    
    
    
    June 2024
76. ZHAO Y, Zheng Y, Fu J, Zhang J, et al
    KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer.
    Br J Cancer. 2024 Jun 29. doi: 10.1038/s41416-024-02772.
    PubMed     Abstract available
    
    
    
77. GULIKERS JL, Otten LS, Hendriks LEL, Winckers K, et al
    Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer.
    Br J Cancer. 2024 Jun 11. doi: 10.1038/s41416-024-02744.
    PubMed     Abstract available
    
    
    
78. KATO T, Yang JC, Ahn MJ, Sakai H, et al
    Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
    Br J Cancer. 2024;130:1679-1686.
    PubMed     Abstract available
    
    
    May 2024
79. YOSHIMURA A, Horinaka M, Yaoi T, Ono H, et al
    Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.
    Br J Cancer. 2024 May 31. doi: 10.1038/s41416-024-02727.
    PubMed     Abstract available
    
    
    
80. MALAPELLE U, Leighl N, Addeo A, Hershkovitz D, et al
    Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02709.
    PubMed     Abstract available
    
    
    
81. JEONG H, Koh J, Kim S, Song SG, et al
    Epithelial-mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer.
    Br J Cancer. 2024 May 10. doi: 10.1038/s41416-024-02698.
    PubMed     Abstract available
    
    
    April 2024
82. LI C, Liu L, You R, Li Y, et al
    Trajectory patterns and cumulative burden of CEA during follow-up with non-small cell lung cancer outcomes: A retrospective longitudinal cohort study.
    Br J Cancer. 2024 Apr 9. doi: 10.1038/s41416-024-02678.
    PubMed     Abstract available
    
    
    
83. MATHIESON L, Koppensteiner L, Dorward DA, O'Connor RA, et al
    Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome.
    Br J Cancer. 2024 Apr 6. doi: 10.1038/s41416-024-02671.
    PubMed     Abstract available
    
    
    
84. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    PubMed     Abstract available
    
    
    
85. GORGULHO J, Roderburg C, Beier F, Bokemeyer C, et al
    Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies.
    Br J Cancer. 2024;130:1013-1022.
    PubMed     Abstract available
    
    
    
86. KANAHORI M, Shimada E, Matsumoto Y, Endo M, et al
    Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8(+) T cell infiltration.
    Br J Cancer. 2024;130:1083-1095.
    PubMed     Abstract available
    
    
    March 2024
87. HARATANI K, Nakamura A, Mamesaya N, Sawa K, et al
    Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02662.
    PubMed     Abstract available
    
    
    
88. FU X, Liu S, Cao D, Li C, et al
    Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
    Br J Cancer. 2024;130:716-727.
    PubMed     Abstract available
    
    
    
89. BLANCO E, Silva-Pilipich N, Bocanegra A, Chocarro L, et al
    Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
    Br J Cancer. 2024;130:869-879.
    PubMed     Abstract available
    
    
    February 2024
90. BLECHTER B, Wong JYY, Chien LH, Shiraishi K, et al
    Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity.
    Br J Cancer. 2024 Feb 22. doi: 10.1038/s41416-024-02592.
    PubMed     Abstract available
    
    
    
91. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Correction: Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02603.
    PubMed    
    
    
    
92. FONT A, Mellado B, Climent MA, Virizuela JA, et al
    Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
    Br J Cancer. 2024;130:434-441.
    PubMed     Abstract available
    
    
    January 2024
93. REN Z, Dharmaratne M, Liang H, Benard O, et al
    Redox signalling regulates breast cancer metastasis via phenotypic and metabolic reprogramming due to p63 activation by HIF1alpha.
    Br J Cancer. 2024 Jan 18. doi: 10.1038/s41416-023-02522.
    PubMed     Abstract available
    
    
    
94. MEZQUITA L, Oulhen M, Aberlenc A, Deloger M, et al
    Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
    Br J Cancer. 2024 Jan 4. doi: 10.1038/s41416-023-02535.
    PubMed     Abstract available
    
    
    
95. LEONETTI A, Verze M, Minari R, Perrone F, et al
    Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
    Br J Cancer. 2024;130:135-142.
    PubMed     Abstract available
    
    
    December 2023
96. SANCHEZ-CASTILLO A, Heylen E, Hounjet J, Savelkouls KG, et al
    Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.
    Br J Cancer. 2023 Dec 30. doi: 10.1038/s41416-023-02553.
    PubMed     Abstract available
    
    
    
97. CHEN B, Yao W, Li X, Lin G, et al
    A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2023 Dec 18. doi: 10.1038/s41416-023-02519.
    PubMed     Abstract available
    
    
    
98. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    PubMed     Abstract available
    
    
    
99. THOMPSON JC, Scholes DG, Carpenter EL, Aggarwal C, et al
    Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors.
    Br J Cancer. 2023;129:1893-1902.
    PubMed     Abstract available
    
    
    November 2023
100. ESLAMI-S Z, Cortes-Hernandez LE, Sinoquet L, Gauthier L, et al
     Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
     Br J Cancer. 2023 Nov 16. doi: 10.1038/s41416-023-02491.
     PubMed     Abstract available
     
     
     
101. QU FJ, Zhou Y, Wu S
     Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases.
     Br J Cancer. 2023 Nov 9. doi: 10.1038/s41416-023-02482.
     PubMed     Abstract available
     
     
     
102. HUNTER B, Argyros C, Inglese M, Linton-Reid K, et al
     Radiomics-based decision support tool assists radiologists in small lung nodule classification and improves lung cancer early diagnosis.
     Br J Cancer. 2023 Nov 6. doi: 10.1038/s41416-023-02480.
     PubMed     Abstract available
     
     
     
103. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
     Correction: Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
     Br J Cancer. 2023 Nov 3. doi: 10.1038/s41416-023-02481.
     PubMed    
     
     
     
104. TANG M, Burgess JT, Fisher M, Boucher D, et al
     Targeting the COMMD4-H2B protein complex in lung cancer.
     Br J Cancer. 2023 Nov 1. doi: 10.1038/s41416-023-02476.
     PubMed     Abstract available
     
     
     
105. SHEN M, Liu S, Toland A, Hsu EC, et al
     ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.
     Br J Cancer. 2023;129:1818-1828.
     PubMed     Abstract available
     
     
     October 2023
106. JANI BD, Sullivan MK, Hanlon P, Nicholl BI, et al
     Personalised lung cancer risk stratification and lung cancer screening: do general practice electronic medical records have a role?
     Br J Cancer. 2023 Oct 25. doi: 10.1038/s41416-023-02467.
     PubMed     Abstract available
     
     
     
107. YANG Z, Zhu J, Yang T, Tang W, et al
     Comprehensive analysis of the lncRNAs-related immune gene signatures and their correlation with immunotherapy in lung adenocarcinoma.
     Br J Cancer. 2023;129:1397-1408.
     PubMed     Abstract available
     
     
     
108. SICARD G, Protzenko D, Giacometti S, Barlesi F, et al
     Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet.
     Br J Cancer. 2023;129:1373-1382.
     PubMed     Abstract available
     
     
     
109. PARRA ER, Ilie M, Wistuba II, Hofman P, et al
     Quantitative multiplexed imaging technologies for single-cell analysis to assess predictive markers for immunotherapy in thoracic immuno-oncology: promises and challenges.
     Br J Cancer. 2023;129:1417-1431.
     PubMed     Abstract available
     
     
     September 2023
110. SHIRASAWA M, Yoshida T, Shiraishi K, Goto N, et al
     Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
     Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02427.
     PubMed     Abstract available
     
     
     
111. GASSLER N, Zhang C, Wenger T, Schnabel PA, et al
     Correction to: Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
     Br J Cancer. 2023 Sep 18. doi: 10.1038/s41416-023-02433.
     PubMed    
     
     
     
112. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
     Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
     Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
     PubMed     Abstract available
     
     
     
113. YANG Y, Xu S, Jia G, Yuan F, et al
     Integrating genomics and proteomics data to identify candidate plasma biomarkers for lung cancer risk among European descendants.
     Br J Cancer. 2023 Sep 7. doi: 10.1038/s41416-023-02419.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum